Your browser doesn't support javascript.
loading
Dalbavancin in the treatment of acute bacterial skin and skin structure and other infections: a safety evaluation.
Righi, Elda; Visentin, Alessandro; Meroi, Marco; Carrara, Elena; Tacconelli, Evelina.
Afiliación
  • Righi E; Infectious Diseases Division, Diagnostic and Public Health Department, University of Verona, Verona, Italy.
  • Visentin A; Infectious Diseases Division, Diagnostic and Public Health Department, University of Verona, Verona, Italy.
  • Meroi M; Infectious Diseases Division, Diagnostic and Public Health Department, University of Verona, Verona, Italy.
  • Carrara E; Infectious Diseases Division, Diagnostic and Public Health Department, University of Verona, Verona, Italy.
  • Tacconelli E; Infectious Diseases Division, Diagnostic and Public Health Department, University of Verona, Verona, Italy.
Expert Opin Drug Saf ; 21(9): 1171-1181, 2022 Sep.
Article en En | MEDLINE | ID: mdl-36093622
INTRODUCTION: Dalbavancin is a second-generation lipoglycopeptide approved since 2014 to treat acute bacterial skin and skin-structure infections (ABSSSI). Dalbavancin is characterized by Gram-positive activity and novel pharmacokinetic properties allowing prolonged terminal half-life andonce weekly dosing . A good safety profile was reported in clinical trials . AREAS COVERED: Dalbavancin safety and tolerability from trials and post-marketing studies were reviewed. While most reports included predominantly ABSSSI, two clinical trials and recent observational studies have explored the use of dalbavancin for off-label indications, mainly including bloodstream and osteoarticular infections. EXPERT OPINION: The occurrence of drug-related adverse effects (AE) was similar between dalbavancin and comparators in clinical trials enrolling patients with ABSSSI. Most common AE included gastrointestinal symptoms, infusion reaction, and hypersensitivity. Low rates of drug discontinuation and serious AE were reported across studies. In the past 5 years, several observational studies have reported safety data on the use of dalbavancin, confirming its favorable safety profile. Nevertheless, data from dalbavancin off-label use, often derived from prolonged (>2 weeks) treatments with variable dosing regimens, were mainly retrospective and lacked comparators. Further research is required to allow a reliable analysis of short- and long-term dalbavancin-related AE in non-ABSSSI.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Antibacterianos Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Antibacterianos Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Expert Opin Drug Saf Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido